Difenda 0.02 mg/3 mg, 28 tablets — Made in Spain — Free Delivery

Difenda film-coated tablets are indicated for oral contraception.

Active ingredients: drospirenone; ethinylestradiol;

1 pink tablet contains: ethinylestradiol 0.02 mg and drospirenone 3 mg;

Excipients: lactose monohydrate, corn starch; povidone, croscarmellose sodium; polysorbate 80 magnesium stearate;

Film shell: Opadry II Pink, which contains polyvinyl alcohol, titanium dioxide (E 171), macrogol, talc, yellow iron oxide (E172), red iron oxide (E172), black iron oxide (E172);

1 white placebo tablet contains:

Excipients: lactose, povidone, magnesium stearate;

Film shell: Opadry II white, containing: polyvinyl alcohol, titanium dioxide (E 171), macrogol, talc.

The presence or risk of developing venous thromboembolism (VTE).

The presence or risk of developing arterial thromboembolism (ATE).

Severe renal failure or acute renal failure.

The presence of liver tumors at present or in history (benign or malignant).

Vaginal bleeding of unknown etiology.

Hypersensitivity to the active substances or to any of the components of the preparation.

Tablets should be taken daily according to the order indicated on the package, at about the same time, with a small amount of liquid if necessary. Tablets should be taken continuously. The preparation is taken 1 tablet / day for 28 days in a row. Taking tablets from each subsequent package should be started the next day after the end of the previous package. Usually, withdrawal bleeding starts 2-3 days after the start of the placebo pills (last row) and may not end before the pills from the next pack start.

Contraindicated.

The preparation is indicated for use as prescribed by a doctor only after the onset of stable menstruation.

Does not affect.

So far, there are no data from clinical studies regarding the overdose of Difenda tablets. Based on the general experience with the use of combined oral contraceptives, overdose may cause nausea, vomiting, and in young girls, vaginal bleeding. There is no specific antidote; treatment should be symptomatic.

Mental disorders: emotional lability.

From the nervous system: headache.

From the gastrointestinal tract: nausea.

From the reproductive system and mammary glands: soreness of the mammary glands, metrorrhagia, amenorrhea.

The use of contraceptive steroids may affect the results of certain laboratory tests, such as biochemical parameters of liver, thyroid, adrenal and kidney function, plasma concentrations of transport proteins such as corticosteroid-binding globulin, plasma concentrations of lipid/lipoprotein fractions, indicators of carbohydrate metabolism, coagulation and fibrinolysis. Usually these changes are within the normal range. Drospirenone increases the activity of renin and aldosterone in blood plasma, induced by its moderate antimineralocorticoid activity.

Store in original packaging at temperatures not exceeding 25°C.

Keep out of the reach of children.

Shelf life - 3 years.